Kolexia
Puech Julien
Médecine générale
Centre Hospitalier des Pays de Morlaix
Morlaix, France
29 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} COVID-19 Convalescence Infections à papillomavirus Breakthrough Infections Maladies du rein Insuffisance rénale chronique Tumeurs osseuses Carcinome épidermoïde Carcinomes

Industries

Sanofi
1 collaboration(s)
Dernière en 2016
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Two complete genomes recovered from inverted sinonasal papillomas in humans.
Microbiology resource announcements   05 mars 2024
Nirmatrelvir and Ritonavir combination in COVID-19 patients with advanced chronic kidney disease.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America   30 décembre 2023
Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients.
Med (New York, N.Y.)   01 novembre 2023
Julien Puech prépare la Nuit du Rouergue - ladepeche.fr
La Dépêche du Midi    25 septembre 2023
Digital Papillary Adenocarcinoma in Nonacral Skin: Clinicopathologic and Genetic Characterization of 5 Cases.
The American journal of surgical pathology   31 juillet 2023
Human papillomavirus genotype distribution by cytological status and associated risk factors in the general population of Congolese women living in urban and rural areas: Implications for cervical cancer prevention.
Infectious diseases now   14 juillet 2023
Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients.
medRxiv : the preprint server for health sciences   30 mai 2023
Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.
Nature communications   14 février 2023
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies.
bioRxiv : the preprint server for biology   21 novembre 2022
Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection.
Med (New York, N.Y.)   05 octobre 2022